Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Wenwei Xu

Xiquan Zhang

Aiming Zhang

Zhou Zhou

Mingming Li

Shufeng Wu

Minmin Kong

This application belongs to the field of pharmaceutical technology, and relates to the crystals of glycyrrhizic acid derivatives, their crystalline and pharmaceutical compositions, and medical use thereof, and, in particular, to the crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E of magnesium isoglycyrrhizinate, the method of preparing the crystals, the crystalline and pharmaceutical compositions containing the crystals, and medical use thereof. The crystalline forms prepared according to this application have overcome the defects of the compound of Formula I prepared according to the prior art, such as solid caking, difficult filtration, hard drying, and poor clarity. They are also suitable for industrial production, and capable of improving product safety.

Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof

The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)&#x2014;N&#x2014;((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40&#xb0;, 20.28&#xb0;, 20.94&#xb0;, 22.02&#xb0;, and 24.46&#xb0;, represented by 2&#x3b8;. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value. 

Crystalline sulfamide compound

Growing community of inventors

Jiangsu, China

Wenwei Xu